Repsol's bio-attributed polyolefins to reduce the medical sector's carbon footprint

The company offers its pioneering range of bio-attributed polyolefins, a first-generation range made from sustainable organic oils, and second-generation bio-attributed, made from organic waste, for pharmaceutical applications.

Repsol's biobased range is a game-changing medical sector solution, designed to meet the industry's growing demand for eco-friendly solutions. With a strong focus on eco-design, the range replaces traditional feedstock from refineries with biobased feedstock from sustainable crops oil or the reuse of organic waste.

The new advanced “biobased range” from Repsol offers a negative carbon footprint on a cradle-to-gate methodology under the ISO 14067 standard, removing more CO₂ from the atmosphere than the emissions in the supply chain processes. Replacing the traditional feedstock used at their industrial sites with this new biobased feedstock, which has previously removed CO₂ from the atmosphere by photosynthesis during its plantation life cycle, improves carbon footprint to -1 tCO₂/t for their first-generation polyolefins and -2,5 tCO₂/t for their second-generation polyolefins. Furthermore, this biobased range is ISCC Plus certified for traceability through mass balance. In addition, the new bio-attributed polyolefins meet these applications' strict cleanliness and safety requirements.

These eco-friendly solutions are already available to Repsol's pharmaceutical packaging and medical devices clients in the European market, meeting the European pharmacopeia standards and offering healthcare manufacturers an opportunity to reduce CO₂ emissions while prioritizing product safety. While the global medical devices market is projected to grow significantly due to increasing healthcare expenditure, advancements in medical technology, and the growing demand for non-invasive medical procedures, there is an increasing commitment towards reducing its carbon footprint. Repsol continues to align with its clients' sustainability objectives within the healthcare sector, promoting new investments that will increase the production capacity of circular and lower carbon footprint solutions while reducing the consumption of virgin raw materials.

Repsol's new bio-attributed range of polyolefins marks a significant step in the company's commitment to defossilisation to meet its goal to become a net-zero emissions company by 2050. In addition, Repsol's bio-attributed range offers a unique solution for the healthcare industry to reduce its carbon footprint. AT

www.repsol.com